For research use only. Not for therapeutic Use.
Roquinimex (Cat No.:I005036) is an immunomodulator that inhibits the secretion of TNF-α. It enhances natural killer (NK) cell activity and T lymphocyte-mediated effector functions, making it a novel immunomodulatory drug. Additionally, Roquinimex demonstrates potential as an orally active anti-angiogenic agent, indicating its effectiveness in inhibiting blood vessel formation. These properties suggest that Roquinimex holds promise as an anti-tumor therapy.
| Catalog Number | I005036 |
| CAS Number | 84088-42-6 |
| Molecular Formula | C18H16N2O3 |
| Purity | ≥95% |
| Target | TNF-α |
| Solubility | 10 mM in DMSO |
| Storage | 2-8°C |
| IUPAC Name | 4-hydroxy-N,1-dimethyl-2-oxo-N-phenylquinoline-3-carboxamide |
| InChI | InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3 |
| InChIKey | SGOOQMRIPALTEL-UHFFFAOYSA-N |
| SMILES | CN1C2=CC=CC=C2C(=C(C1=O)C(=O)N(C)C3=CC=CC=C3)O |
| Reference | </br>1:Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine production. Xiao ZY, Zhou WX, Zhang YX, Cheng JP, He JF, Yang RF, Yun LH.Life Sci. 2007 Oct 27;81(19-20):1403-10. Epub 2007 Sep 29. PMID: 17950363 </br>2:Immunomodulation by roquinimex decreases the expression of IL-23 (p19) mRNA in the brains of herpes simplex virus type 1 infected BALB/c mice. Peltoniemi J, Broberg EK, Halenius A, Setala N, Eralinna JP, Salmi AA, Roytta M, Hukkanen V.Clin Exp Immunol. 2004 Aug;137(2):305-12. PMID: 15270847 Free PMC Article</br>3:Reduced gingival fluid flow: a peripheral marker of the pharmacological effect of roquinimex. Lindberg P, Billström A, Kinnby B.Inflammopharmacology. 2003;11(3):267-76. PMID: 15035809 </br>4:Roquinimex inhibits dextran sodium sulfate-induced murine colitis. Liu Q, Wang Y, Wan MX, Zhang XW, Andersson G, Hedlund G, Thorlacius H.Inflamm Res. 2003 Feb;52(2):64-8. PMID: 12665123 </br>5:Absorption and disposition including enterohepatic circulation of (14C) roquinimex after oral administration to healthy volunteers. Strandgården K, Höglund P, Grönquist L, Svensson L, Gunnarsson PO.Biopharm Drug Dispos. 2000 Mar;21(2):53-67. PMID: 11100907 </br>6:Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man. Tuvesson H, Wienkers LC, Gunnarsson PO, Seidegård J, Persson R.Xenobiotica. 2000 Sep;30(9):905-14. PMID: 11055268 </br>7:Dermatologic changes associated with roquinimex immunotherapy after autologous bone marrow transplant. Ohsuga Y, Rowe JM, Liesveld J, Burns RP, Gaspari AA.J Am Acad Dermatol. 2000 Sep;43(3):437-41. PMID: 10954654 </br>8:Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation. Simonsson B, Tötterman T, Hokland P, Lauria F, Carella AM, Fernandez MN, Rozman C, Ferrant A, de Witte T, Zander AR, Meier K, Hansson F, Nilsson BI.Bone Marrow Transplant. 2000 Jun;25(11):1121-7. PMID: 10849523 Free Article</br>9:Metabolism of roquinimex in mouse and rat: an in vitro/in vivo comparison. Tuvesson H, Strandgården K, Nordle O, Gunnarsson PO, Seidegård J, Persson R.Xenobiotica. 2000 Apr;30(4):371-80. PMID: 10821166 </br>10:Dissolution rate-limited absorption and complete bioavailability of roquinimex in man. Strandgârden K, Höglund P, Nordle O, Polacek J, Wännman H, Gunnarsson PO.Biopharm Drug Dispos. 1999 Oct;20(7):347-54. PMID: 10760843 |
